Biodexa Pharmaceuticals PLC ADR

Biodexa Pharmaceuticals PLC ADR represents shares in a clinical-stage biopharmaceutical company incorporated in England and Wales and headquartered in Cardiff, United Kingdom. The company develops a pipeline of innovative treatments targeting diseases with high unmet medical needs, including familial adenomatous polyposis (FAP), type 1 diabetes, TKI-resistant gastrointestinal stromal tumors (GIST), and primary and metastatic brain cancers. Its lead program, eRapa, is a proprietary oral tablet formulation of rapamycin using nanotechnology and pH-sensitive polymers to enhance bioavailability and consistent pharmacokinetics for FAP, where it is advancing toward a phase 3 registration study known as the Serenta trial. MTX240, licensed from Otsuka, is a next-generation molecular glue for TKI-resistant GIST via selective protein degradation. Tolimidone acts as a selective lyn kinase inhibitor for glycemic control in type 1 diabetes through insulin sensitization. MTX110 delivers panobinostat directly to brain tumors via convection-enhanced delivery, bypassing the blood-brain barrier. Biodexa leverages expertise in formulation science and drug delivery platforms to advance therapies for rare and serious conditions.

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Stephen Anthony Stamp

Employees

13

Headquarters

Cardiff, United Kingdom

Website

www.biodexapharma.com